Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

ClinicalTrials.gov ID: NCT00528333

Public ClinicalTrials.gov record NCT00528333. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older With Previously Untreated AML

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess whether there is a survival benefit with lintuzumab given in combination with low dose cytarabine versus low dose cytarabine and placebo in patients with AML.

Study identification

NCT ID
NCT00528333
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Seagen Inc.
Industry
Enrollment
211 participants

Conditions and interventions

Eligibility (public fields only)

Age range
60 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2007
Primary completion
Jul 31, 2010
Completion
Jul 31, 2010
Last update posted
Jan 6, 2015

2007 – 2010

United States locations

U.S. sites
20
U.S. states
13
U.S. cities
19
Facility City State ZIP Site status
Southern Cancer Center Mobile Alabama 36608
Tower Cancer Research Foundation Beverly Hills California 90210
Glendale Memorial Hospital Glendale California 91204
Kenmar Research Institute Los Angeles California 90057
University of California Los Angeles Los Angeles California 90095-1678
Bay Area Cancer Research Group Pleasant Hill California 94523
University of Colorado Cancer Center Aurora Colorado 80045
Lakeland Regional Cancer Center Lakeland Florida 33805
H. Lee Moffitt Cancer Center & Research Institute Tampa Florida 33612
Rush University Medical Center Chicago Illinois 60612
Joliet Oncology-Hematology Associates Joliet Illinois 60435
Michigan State University, Breslin Cancer Center Lansing Michigan 48910
Billings Clinic Cancer Research Billings Montana 59101
Northshore University Hospital, Monter Cancer Center Lake Success New York 11042
Memorial Sloan Kettering Cancer Center New York New York 10065
Cleveland Clinic Foundation Cleveland Ohio 44195
Western Pennsylvania Cancer Institute Pittsburgh Pennsylvania 15224
Cancer Centers of the Carolinas Greenville South Carolina 29601
University of Texas, MD Anderson Cancer Center Houston Texas 77030
Gunderson Clinic La Crosse Wisconsin 54601

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00528333, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 6, 2015 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00528333 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →